18F-grazy-02: 18F-grazy-02 PET/CT: after intravenous injection of 2.96-3.7 MBq/kg body weight of quality-controlled 18F-grazy-02 , a Total-body PET/CT uEXPLORER scanner will be applied.
Study summary
This is an open-label PET/CT study to investigate the safety and clinical monitoring value of 18F-grazy-02 in patients with lymphoma or solid tumors receiving immunotherapy, including immune checkpoint inhibition and CAR-T cell therapy.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria:
1. 18-75 years old;
2. ECOG score 0 or 1 point;
3. Participants with suspected or confirmed non-small cell lung cancer or melanoma who are suggested by the clinicians to conduct PET/CT imaging for tumor diagnosis or staging.
Exclusion Criteria:
1. Pregnant or nursing;
2. Severe hepatic or renal dysfunction;
3. Low WBC (less than 3 x 10\^9/L);
4. Unable to comply with the PET/CT imaging procedures.
Primary outcome measure(s)
Incidence of 18F-grazy-02-emergent Adverse Events — 1 year Any adverse events following the administration of the radiotracer will be monitored.
Biodistribution of 18F-grazy-02 in participants — 1 year The distribution of 18F-grazy-02 in tumors and healthy tissues will be examined through PET/CT imaging.
Trial sites (1)
Facility
City
Region
Status
Peking University Cancer Hospital & Institute
Beijing
Beijing Municipality
Recruiting
More Peking University Cancer Hospital & Institute trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.